|By PR Newswire||
|February 25, 2013 04:01 AM EST||
OXFORD, England and SAN ANTONIO, February 25, 2013 /PRNewswire/ --
Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the results of a phase II clinical study showing that a short course of just four doses of its ToleroMune® cat allergy therapy maintained improvements in patients' symptoms two years after the start of treatment. The results were presented at the 2013 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) in San Antonio, USA on Sunday 24 February.
The phase II study originally measured improvements in nasal and ocular allergy symptoms (Total Rhinoconjunctivitis Symptom Score; TRSS) in 202 patients, following treatment with ToleroMune® therapy or placebo. Two years after the start of the study, and having received no further ToleroMune® treatment, 50 of the original patients returned to reassess their symptoms while exposed to cat allergens. The results show that at the end of the cat allergen challenge, patients who had previously been treated with four doses of ToleroMune® therapy over 12 weeks had a significant improvement in symptoms two years later, compared with placebo (p<0.05; 50.0% TRSS improvement on ToleroMune® treatment vs 14.9% on placebo). These patients also maintained a substantial reduction in symptoms throughout their entire exposure to cat allergens over the four day challenge (38.3% TRSS improvement vs 13.4% on placebo). In addition, the results show that these patients maintained consistent symptom improvements both 12 and 24 months after the start of treatment. The ToleroMune® therapy was well tolerated with a safety profile comparable to placebo.
Commenting on the results, co-author of the AAAAI conference presentation, Professor Mark Larché, Canada Research Chair in Allergy and Immune Tolerance, McMaster University and St. Joseph's Healthcare, Hamilton, said, "Sustaining such a substantial improvement in patients' allergy symptoms two years after the start of the study is remarkable. Achieving this with a short course of just four doses is even more impressive. These results suggest that ToleroMune® therapy has the potential to revolutionise treatment for cat allergy patients."
"These excellent clinical results are extremely encouraging, and strongly support Circassia's decision to progress to phase III at the end of last year," said Steve Harris, Circassia's CEO. "Offering patients sustained symptom control without the need for ongoing treatment is an important objective for allergy therapy. In this study, our ToleroMune® treatment reduced symptoms by two and a half to three times the level achieved by several other allergy therapies in similar studies, and maintained the improvement over a significant period, demonstrating its potential to greatly improve the lives of patients around the world."
About cat allergy
Allergies are a significant global health issue. Allergic rhinoconjunctivitis (ARC) affects up to 30% of adults and 40% of children in developed countries, and its prevalence is rising. ARC reduces quality of life and impacts school and work attendance and performance. In Continental Europe and the USA, cat allergy is one of the most common forms of the disease, and affects 10 - 15% of those with ARC and / or asthma. As cat dander is widespread in the human environment, and widely found in public buildings, patients with cat allergy may experience significant symptoms despite attempting to avoid exposure. Current treatment options include temporary symptom suppression with antihistamines, corticosteroids and cromones, or long-term whole allergen immunotherapy, which can require treatment for three to five years and has the potential to induce life-threatening anaphylactic reactions.
Circassia's cat allergy treatment is based on the company's novel, proprietary ToleroMune® technology. This uses rationally-designed combinations of synthetic peptides to generate regulatory T cells to control allergic responses and induce immune tolerance. Circassia's ToleroMune® cat allergy treatment consists of seven peptides identified from the major cat allergen Fel d 1. It has successfully completed a number of phase II studies, which demonstrate that courses of short, simple treatment can substantially reduce patients' symptoms and have a favourable safety profile. In long-term follow up, patients' symptoms remained greatly improved two years after the start of the study, despite no further treatment after the initial four doses given over 12 weeks. Circassia's cat allergy treatment entered phase III clinical testing in October 2012.
Circassia was founded by a team of highly experienced biotechnology scientists and entrepreneurs. The company is based in the UK on the Oxford Science Park, and its joint venture with McMaster University (Adiga Life Sciences Inc) is located in Hamilton, Canada. Circassia's ToleroMune® technology was developed originally by scientists at Imperial College, London. Having successfully completed five fundraising rounds, Circassia has raised approximately £105 million ($178 million) and is backed by a syndicate of world-class institutional investors, including Imperial Innovations and Invesco Perpetual.
DevOps is being widely accepted (if not fully adopted) as essential in enterprise IT. But as Enterprise DevOps gains maturity, expands scope, and increases velocity, the need for data-driven decisions across teams becomes more acute. DevOps teams in any modern business must wrangle the ‘digital exhaust’ from the delivery toolchain, "pervasive" and "cognitive" computing, APIs and services, mobile devices and applications, the Internet of Things, and now even blockchain.
Feb. 20, 2017 06:45 AM EST Reads: 161
In the first article of this three-part series on hybrid cloud security, we discussed the Shared Responsibility Model and examined how the most common attack strategies persist, are amplified, or are mitigated as assets move from data centers to the cloud. Today, we’ll look at some of the unique security challenges that are introduced by public cloud environments. While cloud computing delivers many operational, cost-saving and security benefits, it takes place in a public, shared and on-demand ...
Feb. 20, 2017 06:30 AM EST Reads: 1,070
Both SaaS vendors and SaaS buyers are going “all-in” to hyperscale IaaS platforms such as AWS, which is disrupting the SaaS value proposition. Why should the enterprise SaaS consumer pay for the SaaS service if their data is resident in adjacent AWS S3 buckets? If both SaaS sellers and buyers are using the same cloud tools, automation and pay-per-transaction model offered by IaaS platforms, then why not host the “shrink-wrapped” software in the customers’ cloud? Further, serverless computing, cl...
Feb. 20, 2017 06:00 AM EST Reads: 1,608
The Software Defined Data Center (SDDC), which enables organizations to seamlessly run in a hybrid cloud model (public + private cloud), is here to stay. IDC estimates that the software-defined networking market will be valued at $3.7 billion by 2016. Security is a key component and benefit of the SDDC, and offers an opportunity to build security 'from the ground up' and weave it into the environment from day one. In his session at 16th Cloud Expo, Reuven Harrison, CTO and Co-Founder of Tufin, ...
Feb. 20, 2017 05:30 AM EST Reads: 4,575
WebRTC is the future of browser-to-browser communications, and continues to make inroads into the traditional, difficult, plug-in web communications world. The 6th WebRTC Summit continues our tradition of delivering the latest and greatest presentations within the world of WebRTC. Topics include voice calling, video chat, P2P file sharing, and use cases that have already leveraged the power and convenience of WebRTC.
Feb. 20, 2017 05:15 AM EST
Information technology (IT) advances are transforming the way we innovate in business, thereby disrupting the old guard and their predictable status-quo. It’s creating global market turbulence. Industries are converging, and new opportunities and threats are emerging, like never before. So, how are savvy chief information officers (CIOs) leading this transition? Back in 2015, the IBM Institute for Business Value conducted a market study that included the findings from over 1,800 CIO interviews ...
Feb. 20, 2017 05:15 AM EST Reads: 1,347
With the proliferation of both SQL and NoSQL databases, organizations can now target specific fit-for-purpose database tools for their different application needs regarding scalability, ease of use, ACID support, etc. Platform as a Service offerings make this even easier now, enabling developers to roll out their own database infrastructure in minutes with minimal management overhead. However, this same amount of flexibility also comes with the challenges of picking the right tool, on the right ...
Feb. 20, 2017 03:30 AM EST Reads: 6,147
“We're a global managed hosting provider. Our core customer set is a U.S.-based customer that is looking to go global,” explained Adam Rogers, Managing Director at ANEXIA, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Feb. 20, 2017 03:15 AM EST Reads: 1,337
Security, data privacy, reliability and regulatory compliance are critical factors when evaluating whether to move business applications from in-house client hosted environments to a cloud platform. In her session at 18th Cloud Expo, Vandana Viswanathan, Associate Director at Cognizant, In this session, will provide an orientation to the five stages required to implement a cloud hosted solution validation strategy.
Feb. 20, 2017 02:00 AM EST Reads: 4,156
In today's uber-connected, consumer-centric, cloud-enabled, insights-driven, multi-device, global world, the focus of solutions has shifted from the product that is sold to the person who is buying the product or service. Enterprises have rebranded their business around the consumers of their products. The buyer is the person and the focus is not on the offering. The person is connected through multiple devices, wearables, at home, on the road, and in multiple locations, sometimes simultaneously...
Feb. 20, 2017 02:00 AM EST Reads: 6,103
"We host and fully manage cloud data services, whether we store, the data, move the data, or run analytics on the data," stated Kamal Shannak, Senior Development Manager, Cloud Data Services, IBM, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Feb. 20, 2017 01:00 AM EST Reads: 5,214
China Unicom exhibit at the 19th International Cloud Expo, which took place at the Santa Clara Convention Center in Santa Clara, CA, in November 2016. China United Network Communications Group Co. Ltd ("China Unicom") was officially established in 2009 on the basis of the merger of former China Netcom and former China Unicom. China Unicom mainly operates a full range of telecommunications services including mobile broadband (GSM, WCDMA, LTE FDD, TD-LTE), fixed-line broadband, ICT, data communica...
Feb. 20, 2017 01:00 AM EST Reads: 832
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...
Feb. 20, 2017 12:45 AM EST Reads: 2,395
Zerto exhibited at SYS-CON's 18th International Cloud Expo®, which took place at the Javits Center in New York City, NY, in June 2016. Zerto is committed to keeping enterprise and cloud IT running 24/7 by providing innovative, simple, reliable and scalable business continuity software solutions. Through the Zerto Cloud Continuity Platform™, organizations can seamlessly move and protect virtualized workloads between public, private and hybrid clouds. The company’s flagship product, Zerto Virtual...
Feb. 20, 2017 12:15 AM EST Reads: 971
As businesses adopt functionalities in cloud computing, it’s imperative that IT operations consistently ensure cloud systems work correctly – all of the time, and to their best capabilities. In his session at @BigDataExpo, Bernd Harzog, CEO and founder of OpsDataStore, will present an industry answer to the common question, “Are you running IT operations as efficiently and as cost effectively as you need to?” He will expound on the industry issues he frequently came up against as an analyst, and...
Feb. 20, 2017 12:00 AM EST Reads: 1,415